Visceral obesity at diagnosis is associated with well-differentiated neuroendocrine neoplasia lower progression free survival

#3413

Introduction: The association of well-differentiated gastroenteropancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. Although the role of the intrinsic clinical, pathological, and molecular factors on GEP-NEN prognosis has been extensively studied, the association of adverse outcomes with obesity and metabolic risk factors was not identified so far.

Aim(s): The aim of the present study was to evaluate whether the presence of obesity, MetS or any MetS individual components at diagnosis also influences WD GEP NEN`s outcomes.

Materials and methods: A cohort of patients with non-localized WD GEP-NETs (n = 81), was classified according to primary tumor site (gastrointestinal or pancreatic), pathological grading (G1 (Ki67 ≤ 2%) and G2 (>3 ≤ 20%) (WHO 2010), disease extension (loco-regional, and metastatic disease) and hormonal secretion syndrome (functioning/non-functioning) and evaluated for the presence of MetS criteria at diagnosis.

Conference:

Presenting Author: Santos A

Authors: Santos A, Rodrigues J, Henrique R, Cardoso M, Monteiro M,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, metabolic syndrome, visceral obesity, overall survival, progression free survival,